Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Meeting Slides

Clinical Practice Guidelines

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV.

US Department of Health and Human Services, 2017.

US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014. A Clinical Practice Guideline.

Centers for Disease Control and Prevention, 2014.

Clinical Resources

AMCP Format for Formulary Submissions. Version 3.1.

Academy of Managed Care Pharmacy, 2012.

The Sourcebook: Essentials of Health Policy. Chapter 5: Health Care Costs.

Alliance for Health Policy Web Site, 2017.

HIV Cost-effectiveness.

Centers for Disease Control and Prevention, 2017.

Suggested Readings

AMCP Partnership Forum: enabling the exchange of clinical and economic information pre-FDA approval.

Academy of Managed Care Pharmacy. J Manag Care Pharm. 2017;23(1):105-112.

CMS to test enhanced medication therapy management model: aims for greater use of pharmacists, cost savings, and better outcomes.

Barlas S. P T. 2016;41(7):423-441.

The impact of comprehensive case management on HIV client outcomes.

Brennan-Ing M, et al. PLoS One. 2016;11(2):e0148865.

Assessment of the level of satisfaction and unmet data needs for specialty drug formulary decisions in the United States.

Choi Y, Navarro RP. J Manag Care Spec Pharm. 2016;22(4):368-375

Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results.

Eron J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAX0205LB.

Expenditures for persons living with HIV enrolled in Medicaid, 2006-2010.

Fleishman JA, et al. J Acquir Immune Defic Syndr. 2016;72(4):408-415.

A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48.

Gallant J, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0105LB.

What are the incentives for Medicare prescription drug plans to consider long-term outcomes and cost?

Hung A, Perfetto EM. J Manag Care Spec Pharm. 2016;22(7):773-778.

A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse.

Kuchinad KE, et al. BMC Res Notes. 2016;9:229.

Phase III Sword 1&2: switch to DTG+RPV maintains virologic suppression through 48 wks.

Lllibre JM, et al. 24th Conference on Retroviruses and Opportunistic Infections; February 13−16, 2017; Seattle, WA. Abstract 44LB.

The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines.

Malone DC. J Manag Care Pharm. 2005;11(suppl 4):S7-S10.

Demographic, insurance, and health characteristics of newly enrolled HIV-positive patients after implementation of the Affordable Care Act in California.

Satre DD, et al. Am J Public Health. 2016;106(7):1211-1213.

Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study.

Sued O, et al. 9th International Antiviral Society Conference on HIV Science. July 23−26, 2017; Paris, France. Abstract MOAB0106LB.

Single- versus multiple-tablet HIV regimens: adherence and hospitalization risk.

Sutton SS, et al. Am J Manag Care. 2016;22(4):242-248.

Systemic market and organizational changes: impact on P&T committees.

Vogenberg FR, et al. P T. 2017;42(1):28-32.

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

A Critical Appraisal of Non-Invasive Technologies in NASH

Informing the Future of NASH Diagnosis and Assessment

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice


Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

A Call to Action

Monoclonal Antibodies for the Prevention and Treatment of COVID-19

Answers to Everyday Practice Challenges in HIV Medicine

A Phone-a-Friend CME Series – Volume 2

What’s New in the Management of COVID-19

Incorporating New Data and Updated Guidelines Into Daily Practice

Strengthening Your COVID-19 Management Technique

Exercising Best Practices for Hospitalized Patients